Introduction
Patients and methods
Patients
Study design
Drugs
Blood sampling and analysis
Response and toxicity evaluation
Statistical analysis
Results
Patient characteristics
Patients (N = 38) NEOZOTAC | |
---|---|
Median Age (range), Years | 49 (34–65) |
WHO-status | |
0 | 34 (89.5 %) |
1 | 2 (5.8 %) |
Unknown | 2 (5.8 %) |
T-classification | |
cT2 | 22 (57.9 %) |
cT3 or cT4 | 16 (42.1 %) |
N-classification | |
cN0 | 19 (50.0 %) |
cN+ | 19 (50.0 %) |
Tumor type | |
Ductal | 27 (71.1 %) |
Lobular | 7 (18.4 %) |
Other | 3 (7.9 %) |
Unknown | 1 (2.6 %) |
Hormone receptor status | |
ER+ and/or PR+ | 33 (86.8 %) |
ER− and PR− | 5 (13.2 %) |
Allocated treatment | |
TAC | 20 (52.6 %) |
TAC+ZA | 18 (47.4 %) |
pCR | |
Yes | 6 (15.8 %) |
No | 31 (81.6 %) |
Unknown | 1 (2.6 %) |
Thyroid function in breast cancer patients during chemotherapy
Association between alterations of thyroid function and side effects during chemotherapy
Side effect (grade II or more) |
N
| Ratio fT4 (%) | ORa (95 % CI) |
P value | Ratio TSH (%) | ORa (95 % CI) |
P value |
---|---|---|---|---|---|---|---|
Neuropathy | Yes 18 | 89 | 2.56 (1.00–6.56) |
0.050
| 200 | 1.02 (0.97–1.07) | 0.517 |
No 12 | 81 | 163 | |||||
Vomiting | Yes 7 | 95 | 3.36 (1.04–10.87) |
0.043
| 163 | 0.99 (0.93–1.05) | 0.664 |
No 23 | 84 | 191 | |||||
Nausea | Yes 20 | 90 | 2.99 (1.07–8.37) |
0.037
| 150 | 0.96 (0.91–1.01) | 0.094 |
No 10 | 80 | 255 | |||||
Alopecia | Yes 13 | 91 | 2.45 (0.98–6.13) | 0.056 | 171 | 0.99 (0.94–1.04) | 0.663 |
No 17 | 83 | 196 | |||||
Fatigue | Yes 27 | 86 | 1.17 (0.38–3.61) | 0.780 | 185 | 1.00 (0.93–1.08) | 0.996 |
No 3 | 84 | 185 | |||||
Mucositis | Yes 10 | 87 | 1.11 (0.56–2.22) | 0.759 | 222 | 1.02 (0.98–1.07) | 0.352 |
No 20 | 86 | 166 | |||||
Diarrhea | Yes 7 | 93 | 2.38(0.91–6.22) | 0.078 | 107 | 0.92 (0.82–1.04) | 0.188 |
No 23 | 84 | 209 | |||||
Neutropenia | Yes 2 | 86 | 0.88 (0.23–3.38) | 0.939 | 320 | 1.05 (0.97–1.13) | 0.640 |
No 28 | 85 | 175 | |||||
Anemia | Yes 3 | 92 | 1.58 (0.57–4.41) | 0.382 | 99 | 0.91 (0.74–1.12) | 0.381 |
No 27 | 86 | 195 | |||||
Thrombocytopenia | Yes 1 | 85 | 0.88 (0.14–5.74) | 0.895 | 548 | 1.21 (0.63–2.31) | 0.569 |
No 29 | 86 | 173 | |||||
Overall grade III/IV | Yes 6 | 85 | 0.86 (0.37–2.00) | 0.730 | 178 | 1.00 (0.94–1.06) | 0.903 |
No 24 | 87 | 187 |
The predictive value of thyroid function on efficacy of chemotherapy
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
OR | 95 % CI |
P value | OR | 95 % CI |
P value | |
Clinical axillary lymph node: Pos versus Neg | 0.94 | 0.16–5.39 | 0.942 | |||
Clinical tumor size: >5cm versus <5cm | 0.61 | 0.10–3.82 | 0.595 | |||
ER+/PR+ receptor: Pos versus Neg | 0.21 | 0.27–1.70 | 0.154 | |||
Total dose of CT | 1.01 | 0.88–1.16 | 0.915 | |||
fT4 | 0.78 | 0.43–1.42 | 0.417 | 0.66 | 0.33–1.29 | 0.223 |
TSH | 3.24 | 1.09–9.70 |
0.035
| 19.7 | 0.77–504 | 0.072 |